Recent Press Releases

Cipla enters into a licensing agreement with Gilead to increase access to Hepatitis C treatment

India, Mumbai, 15th September 2014: Cipla Limited, a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients today announced that...

Mylan Signs Agreement with Gilead to Accelerate Access to Hepatitis C Treatments, Sovaldi® (Sofosbuvir) and Single Tablet Regimen of Ledipasvir/Sofosbuvir, in Developing Countries

PITTSBURGH and HYDERABAD, India, Sept. 15, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Laboratories Limited has entered into an agreement with Gilead...

Gilead Announces Generic Licensing Agreements to Increase Access to Hepatitis C Treatments in Developing Countries

-- Indian companies granted license to produce generic sofosbuvir and investigational single tablet regimen of ledipasvir/sofosbuvir for treatment of chronic hepatitis C -- NEW DELHI--(BUSINESS...

ABSORB II Study Shows Abbott's Dissolving Heart Device Comparable to the World's Leading Heart Stent

- Abbott's Absorb Bioresorbable Vascular Scaffold (BVS) is a revolutionary medical device, used in the heart, that functions like a stent but dissolves over time

<

Amgen Presents Analyses Of Phase 3 Ivabradine Data For The Treatment Of Chronic Heart Failure

Analysis From SHIFT Study Shows Ivabradine Reduced Cardiovascular Death or Hospitalization for Worsening Heart Failure Independent of Baseline Blood Pressure With Similar Safety Profile Across Gro

Lilly Announces CYRAMZA™ Phase III Second-Line Colorectal Cancer Trial Meets Primary Endpoint of Overall Survival

-- Ramucirumab Plus FOLFIRI Improved Survival in Metastatic Colorectal Cancer following Progression on a Bevacizumab-Based Regimen --

IND

New data confirm high efficacy of Gilenya(R) in achieving 'no evidence of disease activity (NEDA)' based on four key measures of MS

(Thomson Reuters ONE via COMTEX) -- Novartis International AG / New data confirm high efficacy of Gilenya(R) in achieving 'no evidence of disease activity (NEDA)' based on four key measures...

Lilly Announces CYRAMZA™ Phase III Second-Line Colorectal Cancer Trial Meets Primary Endpoint of Overall Survival

-- Ramucirumab Plus FOLFIRI Improved Survival in Metastatic Colorectal Cancer following Progression on a Bevacizumab-Based Regimen -- INDIANAPOLIS, Sept. 12, 2014 /PRNewswire/ -- Eli Lilly and...

Amarin Provides Update on ANCHOR Trial SPA Agreement Rescission Appeal

Amarin Provides Update on ANCHOR Trial SPA Agreement Rescission Appeal BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 09/12/14 -- Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical...

Cyclacel Pharmaceuticals, Inc. (CYCC) Appoints Samuel L. Barker, Ph.D. To Board Of Directors

Cyclacel Pharmaceuticals, Inc. (CYCC) Appoints Samuel L. Barker, Ph.D. To Board Of Directors BERKELEY HEIGHTS, N.J., Sept. 11, 2014 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC)...

Baxter Announces Baxalta as the Name of New Global Biopharmaceutical Company

Baxter Announces Baxalta as the Name of New Global Biopharmaceutical Company Separation into two publicly traded companies remains on track for mid-2015 September 10, 2014 04:30 PM Eastern Daylight...

U.S. FDA Approves New Indication for the Use of XTANDI(R) (Enzalutamide) Capsules for Patients With Metastatic Castration-Resistant Prostate Cancer

Approval Based on Improved Overall Survival, Delayed Time to Radiographic Progression and an Overall Positive Benefit-Risk Profile SAN FRANCISCO, CA and TOKYO, JAPAN -- (Marketwired) -- 09/10/14...

Takeda and Orexigen Announce FDA Approval of Contrave® (naltrexone HCI and bupropion HCI) Extended-release Tablets for Chronic Weight Management

Takeda and Orexigen Announce FDA Approval of Contrave® (naltrexone HCI and bupropion HCI) Extended-release Tablets for Chronic Weight Management New Medication for Obese Adults, or Overweight...

At Four Years, Treatment Effect Maintained in More Than Two-Thirds of Patients Who Received Genzyme's Lemtrada in Pivotal Studies

At Four Years, Treatment Effect Maintained in More Than Two-Thirds of Patients Who Received Genzyme's Lemtrada in Pivotal Studies In approximately 70 percent of patients, disability scores improved...

Amgen Announces 23 Abstracts To Be Presented At The American Society for Bone and Mineral Research 2014 Annual Meeting

Data Include Eight Year Analyses of Bone Mineral Density Results for Prolia® (Denosumab) and Further Evidence for Significant Bone-Building With Romosozumab

European Commission grants Lilly and Boehringer Ingelheim's insulin glargine product marketing authorisation in Europe

First biosimilar insulin to receive regulatory approval in the EU

INDIANAPOLIS and RIDGEFIELD, Conn.,

Generic Pharmaceutical Savings Reach Highest-Ever Watermark of $239 Billion in 2013

Ten-year savings hits record at nearly $1.5 trillion according to annual Generic Drug Savings in the U.S. report WASHINGTON, DC (Sept. 10, 2014) — The Generic Pharmaceutical Association (GPhA)...

SPECIAL DRUG SAFETY REPORT DETAILS 49,000 PREVIOUSLY UNDISCLOSED SIDE EFFECT REPORTS

SPECIAL DRUG SAFETY REPORT DETAILS 49,000 PREVIOUSLY UNDISCLOSED SIDE EFFECT REPORTS REPORT AT TEDMED 2014 HIGHLIGHTS DATA MINING'S ROLE IN IMPROVING PUBLIC SAFETY SANTA ROSA, Calif., September 10,...

Gilenya® data confirm reducing brain shrinkage matters for people with MS due to its association with long-term disability progression

Gilenya® data confirm reducing brain shrinkage matters for people with MS due to its association with long-term disability progression New data showed patients who had the highest rates of brain...

FDA Advisory Committee Recommends Against Approval of Actavis' Nebivolol/Valsartan Fixed-Dose Combination NDA for Treatment of Hypertension

FDA Advisory Committee Recommends Against Approval of Actavis' Nebivolol/Valsartan Fixed-Dose Combination NDA for Treatment of Hypertension DUBLIN, Sept. 9, 2014 /PRNewswire/ -- Actavis plc...